Supernus’ ADHD Drug Hits Phase III Endpoint As Filing Beckons
The first of two Phase III trials of Supernus’ ADHD candidate has hit its endpoints in adolescents. The second is due to report in early 2019, setting the stage for regulatory filings.
The first of two Phase III trials of Supernus’ ADHD candidate has hit its endpoints in adolescents. The second is due to report in early 2019, setting the stage for regulatory filings.